PARP1 and ovarian carcinoma: However, poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors have changed the game altogether for individuals with advanced ovarian cancer, especially those carrying breast cancer (BRCA1/2) mutations or so-called homologous recombination deficiencies (HRDs) [1].